Journals / Solunum / 2014 / Cilt: 16 - Sayı: 3

Progesterone Treatment Experience in a Patient with Lymphangioleiomyomatosis Presenting with Recurrent Pneumothorax

Journal
Solunum
Pages
199–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease.
📊
Key Findings & Data:Patients with LAM generally present with dyspnea and spontaneous pneumothorax.
💡
Conclusion & Impact:In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease. Patients with LAM generally present with dyspnea and spontaneous pneumothorax. Today, while there is no proven medical treatment method for LAM, progesterone is among the widely used drugs. In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.

🔖

Cite This Article

TÜLEK, B., KANAT, F., SÜERDEM, M. (2014). Progesterone Treatment Experience in a Patient with Lymphangioleiomyomatosis Presenting with Recurrent Pneumothorax. Solunum, Cilt: 16 - Sayı: 3, 199–202. https://ajindex.com/articles/314322

References (2)

  1. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. Euro- pean Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26. [CrossRef] Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991; 96: 529-35.
  2. Almoosa KF, Ryu JH, Mendez J, Huggins JT, Young LR, Sullivan EJ, et al. Man- agement of pneumothorax in lymphangioleiomyomatosis: effects on recur- rence and lung transplantation complications. Chest 2006; 129: 1274-81. [CrossRef] Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyo- matosis in the UK. Thorax 2000; 55: 1052-7. [CrossRef] Steagall WK, Glasgow CG, Hathaway OM, Avila NA, Taveira-Dasilva AM, Rabel A, et al. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L800-8. [CrossRef] Brant S, Parker MS, Brath LK, Grimes MM. A 47-year-old woman with progressive dyspnea and recurrent pneumothoraces. Chest 2009; 135: 1389-94. [CrossRef] Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomato- sis: abdominopelvic CT and US findings. Radiology 2000; 216: 147-53. [CrossRef] Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173: 105-11. [CrossRef] McCarty KS Jr, Mossler JA, McLelland R, Sieker HO. Pulmonary lymphang- iomyomatosis responsive to progesterone. N Engl J Med 1980; 303: 1461-5. [CrossRef] Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleio- myomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-33. [CrossRef] Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-74. [CrossRef] Kpodonu J, Massad MG, Chaer RA, Caines A, Evans A, Snow NJ, et al. The US experience with lung transplantation for pulmonary lymphangiolei- omyomatosis. J Heart Lung Transplant 2005; 24: 1247-53. [CrossRef]